Dosing

INFLECTRA is dosed identically to Remicade1

Crohn’s disease (CD) (adult)
Recommended dosing in adults with moderately to severely active CD*
Induction phase
Maintenance phase
5 mg/kg
administered intravenously at weeks 0, 2, and 6
5 mg/kg
administered intravenously every 8 weeks
Loss of response
In patients who lose response, consider increasing the dosage
10 mg/kg every 8 weeks
Crohn’s disease (CD) (pediatric)
Recommended dosing in pediatric patients 6 years and older with moderately to severely active CD*
Induction phase
Maintenance phase
5 mg/kg
administered intravenously at weeks 0, 2, and 6
5 mg/kg
administered intravenously every 8 weeks
Ulcerative colitis (UC)
Recommended dosing in adults with moderately to severely active UC*
Induction phase
Maintenance phase
5 mg/kg
administered intravenously at weeks 0, 2, and 6
5 mg/kg
administered intravenously every 8 weeks
Rheumatoid arthritis (RA)
Recommended dosing in adults with moderately to severely active RA
Induction phase
Maintenance phase
3 mg/kg
administered intravenously in combination with methotrexate at weeks 0, 2, and 6
3 mg/kg
administered intravenously in combination with methotrexate every 8 weeks
Incomplete response
Consider increasing the dosage or frequency of treatment
Increase up to 10 mg/kg or treat as often as every 4 weeks
Psoriatic arthritis (PsA)
Recommended dosing in adults with active PsA
Induction phase
Maintenance phase
5 mg/kg
administered intravenously at weeks 0, 2, and 6
5 mg/kg
administered intravenously every 8 weeks
Ankylosing spondylitis (AS)
Recommended dosing in adults with active AS
Induction phase
Maintenance phase
5 mg/kg
administered intravenously at weeks 0, 2, and 6
5 mg/kg
administered intravenously every 6 weeks
Plaque psoriasis (PsO)
Recommended dosing in adults with chronic severe PsO
Induction phase
Maintenance phase
5 mg/kg
administered intravenously at weeks 0, 2, and 6
5 mg/kg
administered intravenously every 8 weeks
*In patients who have had an inadequate response to conventional therapy.
Patients who do not respond by Week 14 are unlikely to respond with continued dosing, and consideration should be given to discontinuing INFLECTRA in these patients.
Bearing in mind that risk of serious infection is increased at higher doses.